1. Home
  2. JHI vs ACOG Comparison

JHI vs ACOG Comparison

Compare JHI & ACOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo John Hancock Investors Trust

JHI

John Hancock Investors Trust

HOLD

Current Price

$13.70

Market Cap

119.3M

Sector

Finance

ML Signal

HOLD

Logo Alpha Cognition Inc.

ACOG

Alpha Cognition Inc.

N/A

Current Price

$5.48

Market Cap

129.4M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
JHI
ACOG
Founded
N/A
2000
Country
United States
Canada
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
119.3M
129.4M
IPO Year
1994
N/A

Fundamental Metrics

Financial Performance
Metric
JHI
ACOG
Price
$13.70
$5.48
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$18.00
AVG Volume (30 Days)
19.8K
76.9K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$132.35
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$11.61
$3.75
52 Week High
$14.51
$10.88

Technical Indicators

Market Signals
Indicator
JHI
ACOG
Relative Strength Index (RSI) 37.86 49.23
Support Level $13.55 $4.96
Resistance Level $13.94 $6.72
Average True Range (ATR) 0.12 0.60
MACD -0.03 0.05
Stochastic Oscillator 8.14 50.00

Price Performance

Historical Comparison
JHI
ACOG

About JHI John Hancock Investors Trust

John Hancock Investors Trust is a United States-based diversified, closed-end management investment company. It seeks to generate income for distribution to its shareholders. The secondary objective of the company is capital appreciation. The portfolio composition of the fund comprises corporate bonds, U.S. government agencies, preferred securities, asset-backed securities, common stocks, short-term investments, and others. The company's portfolio includes Corporate Bonds, Term Loans, U.S Government Agency, and Others.

About ACOG Alpha Cognition Inc.

Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, for which there are limited or no treatment options. The Company's current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Company's commercial development program for ZUNVEYL is primarily focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.

Share on Social Networks: